Artificial intelligence (AI) is coming to the federal Food and Drug Administration (FDA) and the Veterans Administration (VA). Last week, on Oct. 30, the two agencies issued an announcement that they would partner “to launch an interagency testing ground forchealthcare-related artificial intelligence tools.” This development will have consequences for the in vitro diagnostics (IVD) industry, […]
November 4, 2024, Intelligence: Late-Breaking Lab News
- By Robert Michel
- > From the Volume XXXI No. 15 - November 4, 2024 Issue
- Tags: AI, Ambry Genetics, artificial intelligence, AstraZeneca, Beckman Coulter, California Institute of Technology, Counsyl, Delfi Diagnostics, Eli Lilly and Company, FDA, Food and Drug Administration, Haverford Healthcare Advisors, Icahn School of Medicine at Mount Sinai, in vitro diagnostics, Interpath Laboratory, Invitae, IVD, Jeremy Stackawitz, Jet Propulsion Laboratory, lab informatics, Leon Vaitaitis, McKinsey and Co., Nautikon Technologies, Omada Health, Ortho-Clinical Diagnostics-JnJ, Paige, Pathology Services PC, Purdue Pharma, Quest Diagnostics, Quotient Limited, Robert Guigley, Senzo Health, SpeeDx, Thomas J. Fuchs Dr.Sc., VA, Veterans Administration
